Cwm, LLC Sellas Life Sciences Group, Inc. Transaction History

Cwm, LLC

  • $23.3 Billion
  • Q3 2024

A detailed history of Cwm, LLC transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Cwm, LLC holds 10 shares of SLS stock, worth $11. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10
Holding current value
$11
% of portfolio
0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024
BUY
$1.08 - $1.39 $10 - $13
10 New
10 $0
Q3 2022

Oct 27, 2022
BUY
$2.02 - $3.38 $4,040 - $6,760
2,000 New
2,000 $4,000
Q4 2021

Jan 31, 2022
SELL
$5.36 - $9.53 $16 - $28
-3 Closed
0 $0
Q4 2020

Sep 15, 2021
BUY
$2.45 - $17.66 $7 - $52
3 New
3 $0
Q4 2020

Jan 27, 2021
SELL
$2.45 - $17.66 $7 - $52
-3 Closed
0 $0
Q3 2020

Sep 15, 2021
BUY
$1.88 - $3.58 $5 - $10
3 New
3 $0
Q3 2020

Oct 19, 2020
SELL
$1.88 - $3.58 $5 - $10
-3 Closed
0 $0
Q2 2020

Sep 15, 2021
BUY
$1.53 - $3.93 $4 - $11
3 New
3 $0
Q2 2020

Jul 22, 2020
SELL
$1.53 - $3.93 $4 - $11
-3 Closed
0 $0
Q1 2020

Sep 15, 2021
BUY
$1.7 - $4.08 $5 - $12
3 New
3 $0
Q1 2020

Apr 28, 2020
SELL
$1.7 - $4.08 $5 - $12
-3 Closed
0 $0
Q4 2019

Sep 14, 2021
BUY
$3.79 - $10.5 $11 - $31
3 New
3 $0
Q4 2019

Jan 27, 2020
SELL
$3.79 - $10.5 $11 - $31
-3 Closed
0 $0
Q3 2019

Sep 14, 2021
BUY
$6.0 - $11.5 $18 - $34
3 New
3 $0
Q3 2019

Oct 22, 2019
SELL
$6.0 - $11.5 $18 - $34
-3 Closed
0 $0
Q2 2019

Sep 14, 2021
BUY
$5.5 - $59.0 $16 - $177
3 New
3 $0
Q2 2019

Jul 31, 2019
SELL
$5.5 - $59.0 $16 - $177
-3 Closed
0 $0
Q1 2019

Sep 02, 2021
BUY
$46.5 - $83.0 $139 - $249
3 New
3 $0

Others Institutions Holding SLS

# of Institutions
39
Shares Held
5.69M
Call Options Held
1.67M
Put Options Held
74.7K
View Full List

About SELLAS Life Sciences Group, Inc.

SLS Quotes by TradingView
  • Ticker SLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,551,900
  • Market Cap $24.5M
  • Description
  • SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...
More about SLS
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email